The relation of the number of hydrogen-bond acceptors with recoveries of immunosuppressants in DBS analysis

Bioanalysis

Volumn 7, Issue 14, 2015, Pages 1717-1722

  Koster, Remco A ^a   Alffenaar, Jan Willem C ^a   Botma, Rixt ^a   Greijdanus, Ben ^a   Uges, Donald R A ^a   Kosterink, Jos G W ^a,b   Touw, Daan J ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; EVEROLIMUS; HYDROGEN BOND ACCEPTOR; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG DETERMINATION; DRUG ISOLATION; DRUG STRUCTURE; HEMATOCRIT; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR WEIGHT; PROCESS DEVELOPMENT; PROTEIN BINDING; SOLUBILITY; STRUCTURE ANALYSIS; VALIDATION PROCESS; BLOOD; HUMAN; PROCEDURES;

DRIED BLOOD SPOT TESTING; HUMANS; HYDROGEN BONDING; IMMUNOSUPPRESSIVE AGENTS;

EID: 84930588545     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.94     Document Type: Article

References (15)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N. Engl. J. Med. 324(10), 667-674 (1991).
2. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr. Clin. North Am. 50(6), 1283-1300 (2003).
3. Fishman JA. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357(25), 2601-2614 (2007).
4. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49-65 (2010).
5. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31(3), 327-336 (2009).
6. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17(27), 2931-2939 (2011).
7. Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin. Pharmacokinet. 53(11), 961-973 (2014).
8. Koster RA, Alffenaar JW, Greijdanus B, Uges DR. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta 115, 47-54 (2013).
9. Vu DH, Koster RA, Alffenaar JW, Brouwers JR, Uges DR. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 879(15-16), 1063-1070 (2011).
10. den Burger JC, Wilhelm AJ, Chahbouni A, Vos RM, Sinjewel A, Swart EL. Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. Anal. Bioanal. Chem. 404(6-7), 1803-1811 (2012).
11. Capiau S, Stove VV, Lambert WE, Stove CP. Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer. Anal. Chem. 85(1), 404-410 (2013).
12. National Center for Biotechnology Information. PubChem Compound Database; CID=6473866; CID=5284616; CID=6442177; CID=5284373. www. ncbi. nlm. nih. gov
13. Drugbank, open data drug and drug target database. www. drugbank. ca
14. Chemicalize by ChemAxon. www. chemicalize. org
15. Koster RA, Alffenaar JW, Botma R et al. What is the right blood hematocrit preparation procedure for standards and quality control samples for dried blood spot analysis. Bioanalysis 7(3), 345-351 (2015).